MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting

NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONOCTOBER 2, 2023, 4:00pm ET / 22:00 CET MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting IRVINE, CA, and HERSTAL, BELGIUM – October 2, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics […]

Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer

NEWS RELEASE September 26, 2023, 5:00PM EDT / 23:00 CET             Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer IRVINE, CA, and HERSTAL, BELGIUM – September 26, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision […]

MDxHealth Reports Q2 and Half Year 2023 Results

NEWS RELEASE – REGULATED INFORMATION23 AUGUST 2023, 4:00PM EDT / 22:00 CET             MDxHealth Reports Q2 and Half Year 2023 Results Year-over-year Q2 revenues increase by 143% to $16.7 million; excluding GPS, revenues up 29% Q2 gross margin expanded to 59.7% up from 42.4% in the prior year period Amended GPS purchase agreement with […]

Cigna Expands Commercial and Medicare Advantage Coverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test

NEWS RELEASE9 AUGUST 2023, 4PM ET / 22:00 CET             Cigna Expands Commercial and Medicare AdvantageCoverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test Expansion of coverage with Cigna now includes full menu of Company’s precision diagnostic prostate cancer tests, representing more than 15 million lives under coverage IRVINE, CA, and HERSTAL, BELGIUM […]

MDxHealth Announces Results of its Extraordinary General Shareholders’ Meeting

NEWS RELEASE – REGULATED INFORMATION                30 June 2023, 10:00 p.m. CEST MDxHealth Announces Results of its Extraordinary General Shareholders’ Meeting IRVINE, CA, and HERSTAL, BELGIUM – 30 June 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today held an extraordinary general shareholders’ meeting (“EGM“). The items […]

MDxHealth Announces its Extraordinary General Shareholders’ Meeting

             NEWS RELEASE – REGULATED INFORMATION JUNE 5, 2023, 5:30 pm ET/ 23:30 CEST MDxHealth Announces its Extraordinary General Shareholders’ Meeting IRVINE, CA, and HERSTAL, BELGIUM – June 5, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the “Company” or “mdxhealth“), a commercial-stage precision diagnostics company, today invites the holders of securities issued […]

MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings

NEWS RELEASE – REGULATED INFORMATION                25 May 2023, 22:30 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings IRVINE, CA, and HERSTAL, BELGIUM – 25 May 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (“MDxHealth” or the “Company“), a commercial-stage precision diagnostics company, today held its ordinary annual general shareholders’ meeting (“AGM“) […]

MDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference

               NEWS RELEASEMay 23, 2023, 4PM ET/ 22:00 CET MDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference IRVINE, CA, and HERSTAL, BELGIUM – May 23, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage precision diagnostics company, today announced that Michael McGarrity, Chief Executive Officer, will present […]

MDxHealth Reports Q1-2023 Results

NEWS RELEASE – REGULATED INFORMATION15 MAY 2023, 4:00PM EDT / 22:00 CET             MDxHealth Reports Q1-2023 Results Year-over-year revenues increase by 141% to $14.7 million; excluding GPS, revenues up 39% Gross margin expanded by 1,270 basis points over prior year period Positive Local Coverage Determination (LCD), extending coverage for Select mdx test to Medicare […]